

Executive Summary



About:

Bexion Pharmaceuticals is a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN). The lead drug candidate, BXQ-350, activates lysosomal sphingolipid metabolism, inducing tumor cell death and imparting both innate and adaptive immune activity. BXQ-350 is a first-in-class biologic containing the multifunctional, lysosomal activator protein, Saposin C in a nanovesicle formulation.

BXQ-350:

BXQ-350 targets ubiquitous solid tumor features including externalized phosphatidylserine (PS), a tumor agonistic onco-marker. In vitro studies show BXQ-350 catalyzes various cellular processes, including apoptosis, necrosis and other cellular death pathways consistent with activity at the lysosome, with a high specificity to cancer cells. Preclinical and clinical data support identification of mechanism-based biomarkers for BXQ-350 activity.

Completed Adult Phase 1:

Bexion completed a multi-site, first-in-human, Phase 1 clinical study of BXQ-350 for solid tumors and gliomas dosing over 80 heavily pre-treated patients at 4 clinical sites. BXQ-350 demonstrated a very strong safety and tolerability profile and showed preliminary evidence of clinical activity in patients with recurrent brain, CNS cancers and advanced solid tumors (GI and H&N).

Two patients experienced a partial response and remained on study for over two years; six patients experienced disease stabilization for an extended period of time, including two patients that are still on the study after more than five years. Several patients reported complete or partial resolution of long term, persistent CIPN.

Completed Pediatric Phase 1:

Bexion completed a multi-site Pediatric Phase 1 clinical study of BXQ-350 for refractory solid and central nervous system tumors. BXQ-350 was well tolerated at the highest planned dose with no drug related significant dose-limiting toxicities (DLTs) or Severe Adverse Events (SAEs).

Ongoing Clinical Trials:

Bexion is initiating a combination therapy P1b/2 trial in Colorectal Cancer with first patient anticipated Q1/2023. A secondary endpoint in the colorectal trial will be the reduction of CIPN symptoms. In addition, a pilot PK/PD CIPN resolution study has opened with first patient first dose-Oct 17, 2022.

Market Potential:

Bexion Pharmaceuticals is developing treatments in therapeutic areas with significant unmet need and market potential

CIPN

Over 3 million Americans suffer from CIPN
* No approved therapy

Annual Global Market Potential

\$20 Billion +++

Colorectal Cancer

Stage 4 colorectal cancer 5-yr survival rate is between 11-14%

Annual Global Market Potential

\$10 Billion

Regulatory Strategy:

Successful Type B meetings at the FDA have provided guidance and alignment on the development of the colorectal and CIPN programs. Bexion's regulatory strategy remains on track and future meetings will be requested as programs progress.

Intellectual Property

- Worldwide patent coverage and strategy in place, formulation protected until 2038
- Leverage regulatory exclusivities (market, orphan, pediatric), particularly 12-year market exclusivity
- Trade Secret protection of processes and procedures

Senior Management:

Scott Shively, a seasoned C-Suite executive with big pharma and small-to-mid size biopharma experience is President & CEO. Mr. Shively has extensive experience in product commercialization, building and leading multifunctional teams, M&As, business development and fundraising; he has been involved in successful exits for several biopharma companies.

Dr. Ray Takigiku founded Bexion and successfully led them to clinical stage, assuming now the role of Chief Scientific Officer. At Procter & Gamble Pharmaceuticals, Dr. Takigiku was in the leadership team that developed and marketed the blockbuster osteoporosis drug Actonel, and the market leader for ulcerative colitis, Asacol.

Joyce LaViscount, Chief Financial Officer, brings over 30 years of biotech experience spanning start-up organizations to Fortune 100 companies with diverse leadership roles across finance, accounting and operations in both private and public settings. The Board of Directors includes former/current pharma CEOs.

Financing:

To date, the Company has raised \$90M in private funding along with \$6.1M in federal grants from the National Cancer Institute (NCI).

Developing a New Generation of Biologic Immunotherapy to Treat Solid Tumor Cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN)

This presentation contains forward-looking statements, including, without limitation, statements related to Bexion Pharmaceuticals Inc.'s (the "Company") goals, priorities, growth opportunities, new products and solutions, milestones and current and pending clinical trials. All statements contained in this presentation, other than statements of historical fact, are forward-looking statements. The words "anticipate," "plan," "estimate," "expect," "intend," "will," "should," "forecast," "project" and other similar expressions are intended to identify forward-looking statements.

These statements are based on management's current expectations and beliefs. These expectations and beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. By their nature, forward-looking statements involve known and unknown risks, delays, uncertainties, assumptions and other factors because they relate to events and depend on circumstances that will occur in the future, whether or not outside the control of the Company. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, actions by the FDA/HPB/MHRA and other factors. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated, expressed or implied in the forward-looking statements.

You should not place undue reliance on forward-looking statements. The Company does not undertake an obligation to update the forward-looking statements, except as required by applicable law.

This document does not constitute an offer to sell or the solicitation of an offer to buy any security. This document should not be construed as a prospectus or offering document and you should not rely upon it or use it to form the definitive basis for any decision, contract, commitment or action whatsoever, with respect to any proposed transaction or otherwise.

This document is private and confidential. You and your directors, officers, employees, agents and affiliates must hold this document and any oral information provided in connection with this document in strict confidence and may not communicate, reproduce, distribute or disclose it to any other person, or refer to it publicly, in whole or in part at any time except with our prior written consent and in accordance with the research guidelines prepared in connection with this transaction. If you are not the intended recipient of this document, please delete and destroy all copies immediately.

This document was prepared by the Company and the analyses contained in it are based, in part, on certain assumptions made by and information obtained from the Company and/or from other sources. Neither the Company nor any of their respective affiliates, officers, employees or agents, make any representation or warranty, express or implied, in relation to the fairness, reasonableness, adequacy, accuracy or completeness of the information, statements or opinions, whichever their source, contained in this document or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. The information and opinions contained in this document are provided as at the date of the document, are subject to change without notice and do not purport to contain all information that may be required to evaluate the Company. The information in this document is in draft form and has not been independently verified. The Company and their respective affiliates, officers, employees and agents expressly disclaim any and all liability which may be based on this document and any errors therein or omissions therefrom. Neither the Company nor any of their respective affiliates, officers, employees or agents makes any representation or warranty, express or implied, that any transaction has been or may be effected on the terms or in the manner stated in this document, or as to the achievement or reasonableness of future projections, management targets, estimates, prospects or returns, if any.

This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States or any other jurisdiction. This document may not be reproduced, redistributed, published or passed on, directly or indirectly, to any person in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.